The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Carfilzomib-based combinations for Waldenström macroglobulinemia: Real-world experience from a single center.
 
James Di Palma Grisi
No Relationships to Disclose
 
Evan Locke
No Relationships to Disclose
 
David Vesole
Stock and Other Ownership Interests - Abbvie; Amgen; Biogen; Bristol-Myers Squibb; Gilead Sciences; Johnson & Johnson; Lilly; Merck; Novartis
Speakers' Bureau - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Janssen Oncology; Karyopharm Therapeutics; Sanofi; Takeda
 
David Siegel
Stock and Other Ownership Interests - COTA
Honoraria - BMS; Envision Pharma Group; Menarini Silicon Biosystems; Merck; Pfizer; Sebia
Consulting or Advisory Role - Amgen; BMS; Caribou Biosciences; Envision Pharma Group; GlaxoSmithKline; Johnson & Johnson/Janssen; Karyopharm Therapeutics; kelonia; Menarini Silicon Biosystems; Merck; Pfizer; Poseida; Sebia
 
Noa Biran
Honoraria - Abbvie; Bristol-Myers Squibb; Janssen Oncology; Karyopharm Therapeutics; Pfizer
Consulting or Advisory Role - Pfizer; Sanofi/Aventis
Speakers' Bureau - Bristol-Myers Squibb; Janssen
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Karyopharm Therapeutics (Inst)
 
Pooja Phull
Employment - Pfizer (I)
Stock and Other Ownership Interests - Pfizer (I)
 
Harsh Parmar
Honoraria - Cellectar
Consulting or Advisory Role - Cellectar; Sanofi